Bolt as GLP-1 Demand Engine

This makes Bolt look less like a high margin telehealth brand and more like a demand engine sitting on top of Lilly and Novo supply. When Bolt sells Wegovy and Mounjaro at medication cost, the big revenue number mostly reflects drug spend flowing through the business, while Bolt keeps a much smaller slice for consultation, prescribing, monitoring, refill handling, and cold chain fulfillment. That is why revenue can scale very fast without the same gross profit profile as Hims or Ro.

• In practice, Bolt wins by being the cheapest regulated checkout page for branded GLP-1s in the UK. The patient fills out an online intake, a clinician reviews eligibility, the prescription is approved, and the monthly price is set close to drug cost, which let Bolt undercut Boots and Numan on cash pay pricing.
  1 sacra 2 sacra 3 boltpharmacy
• That economics stack is very different from Hims and Ro. Their higher 65% to 80% fulfillment margins come from controlling more of the transaction, through owned pharmacy operations, manufacturer partnerships, and higher margin non drug services, so each prescription generates much more gross profit per dollar of revenue.
  4 sacra 5 sacra
• The tradeoff is that Bolt can grow patients faster than profit dollars. If £200 of monthly revenue includes roughly £160 sent onward to Lilly or Novo and only about £40 kept by Bolt, then volume matters enormously. The operating system around intake, titration, adherence, and refills becomes the real product.
  2 sacra 4 sacra

The next step is clear, Bolt uses branded GLP-1s sold nearly at cost to acquire patients now, then tries to widen margin later through scale, adjacent services, and eventually generic supply when patents loosen. Until then, the company that controls patient acquisition grows fastest, but the drug manufacturers still capture most of the economics.